Phage II Trial of Stathmin as Predictive Biomarker for TPF Induction Chemotherapy in OSCC
Status:
Recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
To investigate the predictive value of stathmin expression as a predictive biomarker in OSCC
patients, who treated with TPF (docetaxel, cisplatin and 5-fluorouracil ) induction
chemotherapy followed by radical surgery and radiotherapy/chemoradiotherapy.